YAP1 and Hutchinson-Gilford progeria syndrome: A reasonable next stage in testing the viability of using verteporfin to treat HGPS would be to design and evaluate strategies to inhibit YAP/TAZ specifically in ECs using EC-targeted delivery systems such as lipid carriers (54) or monocyte membrane-coated nanoparticles (55).